RxDoctor Payments Data

Stanley Watkins, MD

Internal Medicine · Lutz, FLNPI 1902802952

Payments from drug & device makers

$5,750in general payments, 2019–2025

Across 344 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$586
  • Lilly USA, LLC$460
  • AbbVie$400
  • Pfizer$395
  • Amgen$276
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$5,70799%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,750 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,186
Medicare patients
279
Services billed
2,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$94,355
EliquisApixaban64$84,711
XareltoRivaroxaban46$57,018
JardianceEmpagliflozin58$52,089
MounjaroTirzepatide39$47,636
TrulicityDulaglutide25$29,026
RybelsusSemaglutide22$24,772
JanuviaSitagliptin Phosphate21$23,445
FarxigaDapagliflozin Propanediol18$17,938
EntrestoSacubitril/Valsartan18$17,921
Tresiba Flextouch U-200Insulin Degludec13$16,220
JanumetSitagliptin Phos/Metformin Hcl21$14,460
Tresiba Flextouch U-100Insulin Degludec11$10,911
Testosterone22$6,387
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen198$4,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,351$119,127105 claims
PfizerEliquis$395$84,71164 claims
Lilly USA, LLCMounjaro, Trulicity$460$76,66264 claims
Johnson & JohnsonXarelto$209$57,01846 claims
Boehringer IngelheimJardiance$87$52,08958 claims
MerckJanuvia, Janumet$184$37,90542 claims
AstraZenecaFarxiga, Symbicort$586$20,41329 claims
NovartisEntresto$103$17,92118 claims
AbbVieSynthroid$400$4,11044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lutz

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →